China approves mixed-use Covid-19 vaccine trials to start in autumn


China’s medical products regulator has approved local trials for the combined use of the Chinese Sinovac Covid-19 vaccine and a DNA vaccine developed by American biotech company Inovio.The trials are set to begin in the autumn in China and will evaluate the safety and ability of the combined vaccines to induce an immune response in adults, Inovio said.Meanwhile, Sinovac has reported that a study of 300 people aged over 60 showed “a third dose given eight months or more after the second dose…

Leave a Reply